5:54 PM
 | 
Mar 08, 2013
 |  BC Extra  |  Company News

Takeda submits vedolizumab MAA

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) submitted an MAA to EMA for vedolizumab to treat...

Read the full 53 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >